|View printer-friendly version|
|BioLineRx to Report Third Quarter 2014 Results on November 10, 2014|
- Management to hold conference call at
The Company will host a conference call on
The conference call will be available via webcast and can be accessed through the Investor Relations section of BioLineRx’s website, www.biolinerx.com. A presentation will be provided on BioLineRx’s website, to accompany management’s remarks during the conference call. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. To dial into the conference call, please dial 1-866-229-7198 from the U.S. or +972-3-918-0685 internationally.
A replay of the conference call will be available approximately two
hours after completion of the live conference call at www.biolinerx.com.
A dial-in replay of the call will also be available until
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.
BioLineRx’s current portfolio consists of a variety of clinical and
pre-clinical projects, including: BL-1040 for prevention of pathological
cardiac remodeling following a myocardial infarction, which has been
out-licensed to Bellerophon BCM (f/k/a
For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company’s SEC documents, press releases, and events. BioLineRx’s IR app is available on the iTunes App Store as well as the Google Play Store.
Strategic Advisors, Inc.